US Influenza Market: By Drug Class (Anti-viral Drugs, Vaccines), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Others) and Country  

Purchase Option

$ 3000
$ 4400
$ 4600
$ 6900

US Influenza Market size was valued at USD 2.7 billion in 2022 and is poised to grow at a CAGR of 16.2% from 2023-2029. Influenza is an upper respiratory tract disease and is caused by the influenza virus. U.S. Influenza Market is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through a flu cough, droplets from the infected people, sneezing, or talking. The common symptoms that occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, and fatigue, in some cases, people may have vomiting and diarrhea. The complications of the disease may include ear infections, bacterial pneumonia, dehydration, and sinus infections, and sometimes it leads to congestive heart failure and asthma. Influenza commonly occurs in the geriatric population and children less than 5 years of age. The infection may be confirmed by testing the sputum, nose, or throat for the virus. A number of rapid tests are available however polymerase chain reaction that detects the virus's RNA is more accurate. Influenza vaccines are key revenue contributors to the growth of the U.S. influenza market. The U.S. influenza market is in the growing phase, several international players are actively involved in the development of vaccines and drugs to treat influenza. The launch of new products, technological innovations, and approvals from the U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of the U.S. influenza market. For instance, Squires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market. In May 2016, Seqirus received approval from the U.S. Food and Drug Administration for Flucelvax Quadrivalent, which was the first U.S. licensed cell-based quadrivalent influenza vaccine indicated for people aged four years and older. In November 2016, GSK received approval from the U.S. Food and Drug Administration for fluvial Quadrivalent to include use in children aged six months or older

 

 

US Influenza Market Dynamics

The U.S. Influenza market is growing at a significant CAGR due to rise in newborn babies, an increase in geriatric population. Increase in vaccination awareness, favorable reimbursement scenario, and rising investment by companies in research and development activities are the major factors fuelling the growth of U.S. influenza market over the forecast period. The major market players have great pipeline products, initiatives by government bodies such as WHO and CDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of U.S. influenza market over the forecast period. However, limited production capacity, a high level of required investment, and stringent regulatory policies for new product approvals might hamper the growth of U.S. Influenza market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increase in prices of influenza diagnostic kits and reagents also hinder the U.S. Influenza market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

U S Influenza Market Segmentation

By Drug Class
    • Zanamivir
    • Oseltamivir
    • Amantadine
    • Rimantadine
    • Others
    • Interferons
  • Vaccines
    • Trivalent
    • Quadrivalent
By Route of Administrat
  • Oral
  • Parenteral
  • Others
By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Others

Frequently Asked Questions

The size of the us influenza market was valued at USD 2.7 billion in 2022

The us influenza market key players are AstraZeneca (U.K.) F. Hoffmann-La Roche (Switzerland) GlaxoSmithKline plc (U.K.) Novartis AG (Switzerland) Sanofi (France) Seqirus (U.K.) Protein Sciences Corporation (U.S.)

Rising Government Initiatives for Spreading Awareness

1. Executive Summary
2. U.S. Influenza Market Introduction
2.1. Drug Class Type
2.2. Route of Administration
2.3. Distribution Channel
3. U.S. Influenza Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. U.S. Influenza Market Dynamics Factors Impact Analysis
3.6. U.S. Influenza Market Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. U.S. Influenza Market Product Innovations
4. U.S. Influenza Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. U.S. Influenza Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029
5.1. Anti Viral Drugs
5.1.1. Zanamivir
5.1.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Oseltamivir
5.1.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Amantadine
5.1.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Rimantadine
5.1.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
5.1.5. Others
5.1.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.5.3. Market Opportunity Analysis
5.2. Vaccines
5.2.1. Trivalent
5.2.1.1. Market Analysis, 2013-2019 and Forecast, 2019-2026 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.1.3. Market Opportunity Analysis
5.2.2. Quadrivalent
5.2.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.2.3. Market Opportunity Analysis
6. U.S. Influenza Market Forecast, By Route of Administration, 2018 - 2022 and Forecast, 2023 - 2029
6.1. Oral
6.1.1. Market Analysis, 2013-2019 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
7. U.S. Influenza Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029
7.1. Hospital pharmacies
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Retail pharmacies
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. U.S. Influenza Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
8.1. Drug Class Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Anti-viral drugs
8.1.1.1. Zanamivir
8.1.1.2. Oseltamivir
8.1.1.3. Amantadine
8.1.1.4. Rimantadine
8.1.1.5. Others
8.1.1.6. Interferons
8.1.2. Vaccines
8.1.2.1. Trivalent
8.1.2.2. Quadrivalent
8.2. Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Oral
8.2.2. Parenteral
8.2.3. Others
8.3. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others
8.4. U.S. Influenza Market Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel and Country, 2023 - 2029
8.5. U.S. Influenza Market Dynamics Trends
9. Competition Landscape
9.1. Strategic Dashboard of Top Market Players
9.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
9.2.1. AstraZeneca (UK)
9.2.2. F. Hoffmann-La Roche (Switzerland)
9.2.3. GlaxoSmithKline plc (UK)
9.2.4. Novartis AG (Switzerland)
9.2.5. Sanofi (France)
9.2.6. Seqirus (UK)
9.2.7. Protein Sciences Corporation (U.S.)
9.2.8. Emergent Biosolutions (U.S.)
9.2.9. BioCryst Pharmaceuticals.Inc (U.S.)
9.2.10. Alvogen (South Korea)
9.2.11. Medimmune Inc. (U.S.)
9.2.12. DynPort Vaccine Company, LLC. (U.S.)
9.2.13. Abbott Laboratories (U.S.)
10. Research Methodology
11. Key Assumptions and Acronyms
  • AstraZeneca (U.K.)
  • F. Hoffmann-La Roche (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Seqirus (U.K.)
  • Protein Sciences Corporation (U.S.)
  • Emergent Biosolutions (U.S.)
  • BioCryst Pharmaceuticals.Inc (U.S.)
  • Alvogen (South Korea)
  • Medimmune Inc. (U.S.)
  • DynPort Vaccine Company, LLC. (U.S.)
  • Abbott Laboratories (U.S.)